Pharmacovigilance and Drug Safety Software Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 2.09 Bn

Forecast Year, 2035

USD 5.06 Bn

CAGR, 2026 - 2035

9.24%

Report Coverage

Global

What is the Pharmacovigilance and Drug Safety Software Market?

The global pharmacovigilance and drug safety software market size is calculated at USD 2.09 billion in 2025 and is predicted to increase from USD 2.28 billion in 2026 to approximately USD 5.06 billion by 2035, expanding at a CAGR of 9.24% from 2026 to 2035.

Pharmacovigilance and Drug Safety Software Market Key Takeaways

• In terms of revenue, the global pharmacovigilance and drug safety software market was valued at USD 2.09 billion in 2025.
• It is projected to reach USD 5.06 billion by 2035.
• The market is expected to grow at a CAGR of 9.21% from 2026 to 2035.
• North America dominated the global pharmacovigilance and drug safety software market with the largest share of 51.50% in 2025.
• Asia Pacific is expected to grow at the fastest CAGR between 2025 and 2035.
• By software type, the adverse event reporting software segment contributed the biggest market share of 38.50% in 2025.
• By software type, the signal detection software segment is expected to grow at a significant CAGR over the projected period.
• By delivery mode, the on-premise segment captured the highest market share of 46.50% in 2024.
• By delivery mode, the cloud-based software segment is anticipated to grow at a significant CAGR from 2026 to 2035.
• By functionality, the case data entry and processing segment held the major market share of 333.50% in 2025.
• By functionality, the regulatory submission and signal management segment is expected to expand at a significant CAGR from 2026 to 2035.
• By end user, the pharma and biotech companies segment generated the largest market share of 54.50% in 2025.
• By end user, the regulatory agencies and CROs segment is expected to grow at the fastest CAGR between 2026 and 2035.

What is the Pharmacovigilance and Drug Safety Software Market?

The pharmacovigilance and drug safety software market comprises specialized digital platforms and tools used throughout the lifecycle of pharmaceutical and biological products to detect, assess, monitor, and prevent adverse drug reactions (ADRs) and other drug-related issues. These solutions streamline case intake, signal detection, regulatory reporting, data integration, and compliance, supporting manufacturers, regulators, and service providers in ensuring patient safety and meeting global pharmacovigilance standards (such as FDA, EMA, MHRA, PMDA, and WHO Uppsala Monitoring Centre guidelines). These systems are essential for enabling automated workflows, AI-driven signal analysis, real-time reporting, and integration with electronic health records (EHRs), safety databases, and spontaneous reporting systems. The market is growing rapidly due to rising ADR incidences, stringent regulations regarding drug safety, and increased adoption of automation in pharmacovigilance processes.

How is AI Impacting the Pharmacovigilance and Drug Safety Software Market?

Artificial intelligence is transforming the market for pharmacovigilance and drug safety software by improving signal detection, automating case processing, and providing predictive analytics for better patient outcomes. AI-powered tools can analyze vast datasets from sources like social media and electronic health records to detect potential adverse drug reactions more quickly and effectively than traditional methods. This leads to faster safety signal detection, improved risk assessment, and, ultimately, safer drugs. AI also facilitates predictive analytics and personalized safety assessments, contributing to better patient outcomes.

What are the Key Trends in the Pharmacovigilance and Drug Safety Software Market?

• Growing Pharmaceutical research and development Funding:Increased investment in pharmaceutical research and development leads to more drug approvals and, consequently, a greater demand for post-market surveillance. This is furthered by raising awareness about the importance of pharmacovigilance among healthcare professionals.
• Demand for Cloud-Based Solutions: The adoption of cloud-based solutions (SaaS) is expected to drive the growth of the on-demand software segment, offering scalability and cost-effectiveness of cloud-based PV software is also contributing to market growth.
• Adoption by Outsourcing Companies:Contract research organizations (CROs), business process outsourcing (BPO) firms, and other outsourcing firms are increasingly adopting PV software to handle the growing volume of drug safety data, further contributing to market growth.
• Stringent Regulatory Requirements:Stringent regulatory bodies like the FDA and EMA are intensifying safety regulations, increasing pressure on pharmaceutical companies to manufacture safe drugs and evaluate both pre- and post-market drug surveillance, driving the adoption of PV software.
• Technological Advancements:Innovations in areas like AI and ML are enhancing the accuracy and efficiency of drug safety assessments and data analysis within these software solutions, necessitating more robust monitoring and reporting systems.

Pharmacovigilance and Drug Safety Software Market Outlook

[[market_outlook]]

Market Scope

Market Dynamics

Drivers

Increasing Occurrence of Adverse Drug Reactions (ADRs)

A key driver in the pharmacovigilance and drug safety software market is the rising occurrence of adverse drug reactions (ADRs). This increase, observed in both clinical trials and post-market surveillance, calls for robust systems for detection, evaluation, and management. Increased awareness of drug safety and stringent regulatory standards drive the demand for advanced software solutions to manage and reduce adverse effects caused by drugs. Regulatory agencies, such as the FDA and EMA, are imposing strict guidelines, prompting companies to adopt more sophisticated software to ensure compliance. Additionally, the growing use of pharmacovigilance and drug safety software by outsourcing firms such as CROs and CMOs further propels market growth, as these entities handle large data volumes and require efficient systems.

Restraint

High Cost of Implementation and Maintenance

The primary restraint in this market is the high cost of implementation and maintenance, especially for small and medium-sized enterprises. This includes expenses related to software licenses, infrastructure, and ongoing support. Integrating new pharmacovigilance systems with existing IT infrastructure can be complex and costly, particularly for organizations with legacy systems. Maintaining these systems requires specialized personnel and continual updates to meet evolving regulations, which can impose a significant financial burden on smaller businesses. Moreover, linking pharmacovigilance software with other healthcare IT systems, such as EHRs and LIMS, can be challenging, requiring extensive customization that adds to costs and complexity.

Opportunity

Integration of Advanced Technologies

A significant opportunity for the pharmacovigilance and drug safety software market lies in the integration of advanced technologies, such as AI and ML. This trend is driven by the need for more efficient and precise data analysis in pharmacovigilance, especially for identifying adverse drug reactions and ensuring regulatory compliance. These technologies are integrated into pharmacovigilance software to automate tasks such as adverse event reporting, analyzing large datasets, and predicting potential safety signals. This accelerates the detection of safety issues and streamlines decision-making, enabling the identification of previously unknown safety concerns and enhancing drug safety monitoring. Moreover, expanding pharmacovigilance practices in emerging markets with a growing pharmaceutical industry presents new growth opportunities.

Pharmacovigilance and Drug Safety Software Market Segment Insights

[[segment_insights]]

Pharmacovigilance and Drug Safety Software Market Regional Insights

[[regional_insights]]

Pharmacovigilance and Drug Safety Software Market Value Chain Analysis

[[value_chain]]

Pharmacovigilance and Drug Safety Software Market Companies

[[market_company]]

Other Major Key Players

• IQVIA
• AB Cube
• Ennov
• Extedo
• Sparta Systems (a Honeywell company)
• Sarjen Systems
• Max Application
• TCS ADD Safety (Tata Consultancy Services)
• Indegene
• Foresight Group International
• Navitas Life Sciences
• Bioclinica (now part of Clario)
• Online Business Applications Inc. (Argus safety partner)
• Medidata Solutions (Dassault Systemes)
• Polaris Group
• RxLogix
• Cognizant (PV technology services)

Segments Covered in the Report

[[segment_covered]]